Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Vaccine Chief Horiuchi to Bow Out at March-End
March 30, 2022
- PMD Law Amendment Bill to Enter Diet Debate March 31, CDP’s Counter-Legislation Too
March 30, 2022
- Japan Grants Orphan Status to Tafinlar, Mekinist, and 4 More APIs
March 30, 2022
- Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
- Govt’s Avigan Purchase Was a Result of Pursuing Possible Scenarios: PM
March 29, 2022
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- MHLW to Work Out Physician Payment Disclosure Method with Drug Makers towards Amendment of Clinical Research Law
March 28, 2022
- MHLW Panel OKs 84 More Health Damage Claims for COVID-19 Vaccines
March 28, 2022
- Japan Govt OKs 1.3 Trillion Yen Reserve Fund Use for COVID Measures
March 28, 2022
- PMDA Reviewing Safety Risks for Dexamethasone, Teicoplanin
March 28, 2022
- MHLW Study Group Proposes Using Private Data to Monitor Vaccine Distribution and Shortages
March 28, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
- Precedex Gets 1st Designation as Drug for Specific Use
March 25, 2022
- MHLW Study Group Kicks Off Discussions on Use of Pseudonymously Processed Information
March 25, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
- CEFP Calls for Planned Healthcare Investments over Years
March 24, 2022
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
- PMDA to Publish Examples of Shortfalls Found in GMP Inspections
March 24, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…